Compare Stocks: STE, BSX, EW, and BDX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BDX Becton, Dickinson and Company	$176.53 -0.2%	$154.37	$127.59 ▼ $187.35	$48.64B	0.19	1.89 million shs	1.85 million shs
BSX Boston Scientific	$49.35 +0.1%	$45.75	$42.20 ▼ $109.50	$71.53B	0.56	20.14 million shs	11.44 million shs
EW Edwards Lifesciences	$89.65 -0.1%	$88.19	$72.30 ▼ $96.29	$51.62B	0.85	5.10 million shs	2.44 million shs
STE STERIS	$237.70 +0.1%	$214.86	$195.14 ▼ $269.44	$23.17B	0.91	770,609 shs	804,021 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BDX Becton, Dickinson and Company	0.00%	+6.22%	+16.02%	+23.35%	-8.84%
BSX Boston Scientific	0.00%	+5.58%	+10.48%	-7.45%	-52.19%
EW Edwards Lifesciences	0.00%	+4.04%	-2.78%	+16.26%	+14.39%
STE STERIS	0.00%	+3.91%	+10.17%	+17.70%	-2.21%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BDX Becton, Dickinson and Company	$176.53 -0.2%	$154.37	$127.59 ▼ $187.35	$48.64B	0.19	1.89 million shs	1.85 million shs
BSX Boston Scientific	$49.35 +0.1%	$45.75	$42.20 ▼ $109.50	$71.53B	0.56	20.14 million shs	11.44 million shs
EW Edwards Lifesciences	$89.65 -0.1%	$88.19	$72.30 ▼ $96.29	$51.62B	0.85	5.10 million shs	2.44 million shs
STE STERIS	$237.70 +0.1%	$214.86	$195.14 ▼ $269.44	$23.17B	0.91	770,609 shs	804,021 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BDX Becton, Dickinson and Company	0.00%	+6.22%	+16.02%	+23.35%	-8.84%
BSX Boston Scientific	0.00%	+5.58%	+10.48%	-7.45%	-52.19%
EW Edwards Lifesciences	0.00%	+4.04%	-2.78%	+16.26%	+14.39%
STE STERIS	0.00%	+3.91%	+10.17%	+17.70%	-2.21%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BDX Becton, Dickinson and Company	2.41	Hold	$185.00	4.80% Upside
BSX Boston Scientific	2.71	Moderate Buy	$71.62	45.11% Upside
EW Edwards Lifesciences	2.74	Moderate Buy	$100.27	11.85% Upside
STE STERIS	2.75	Moderate Buy	$271.33	14.15% Upside

Current Analyst Ratings Breakdown

Latest STE, BSX, EW, and BDX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/7/2026	BDX Becton, Dickinson and Company	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D+)
8/7/2026	BDX Becton, Dickinson and Company	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$195.00
8/7/2026	BDX Becton, Dickinson and Company	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Sector Perform	$175.00 ➝ $180.00
8/7/2026	BDX Becton, Dickinson and Company	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sector Perform ➝ Hold
8/7/2026	BDX Becton, Dickinson and Company	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$198.00 ➝ $204.00
8/7/2026	BDX Becton, Dickinson and Company	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$161.00 ➝ $175.00
8/7/2026	BDX Becton, Dickinson and Company	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$161.00 ➝ $170.00
8/7/2026	STE STERIS	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$275.00 ➝ $270.00
8/7/2026	STE STERIS	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$270.00 ➝ $275.00
8/6/2026	BDX Becton, Dickinson and Company	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$210.00
8/5/2026	BDX Becton, Dickinson and Company	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Hold	$163.00 ➝ $182.00

(Data available from 8/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BDX Becton, Dickinson and Company	$22.48B	2.16	$23.05 per share	7.66	$88.58 per share	1.99
BSX Boston Scientific	$20.07B	3.56	$4.04 per share	12.22	$16.49 per share	2.99
EW Edwards Lifesciences	$6.07B	8.51	$2.85 per share	31.46	$17.81 per share	5.03
STE STERIS	$5.94B	3.90	$15.21 per share	15.63	$73.39 per share	3.24

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BDX Becton, Dickinson and Company	$1.68B	$3.32	53.17	13.24	12.47	4.52%	14.84%	6.93%	N/A
BSX Boston Scientific	$2.90B	$2.47	19.98	14.43	1.08	17.50%	19.28%	10.89%	10/28/2026 (Estimated)
EW Edwards Lifesciences	$1.07B	$1.74	51.52	26.52	2.25	15.43%	15.68%	12.05%	10/29/2026 (Estimated)
STE STERIS	$782.30M	$8.18	29.06	19.42	N/A	13.34%	14.34%	9.66%	N/A

Latest STE, BSX, EW, and BDX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q3 2026	BDX Becton, Dickinson and Company	$3.14	$3.23	+$0.09	$1.37	$4.89 billion	$4.98 billion
8/5/2026	Q1 2027	STE STERIS	$2.49	$2.59	+$0.10	$2.04	$1.49 billion	$1.49 billion
7/29/2026	Q2 2026	BSX Boston Scientific	$0.83	$0.86	+$0.03	$0.61	$5.38 billion	$5.44 billion
7/23/2026	Q2 2026	EW Edwards Lifesciences	$0.7430	$0.78	+$0.0370	$0.42	$1.70 billion	$1.74 billion
5/11/2026	Q4 2026	STE STERIS	$2.86	$2.83	-$0.03	$2.24	$1.59 billion	$1.59 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BDX Becton, Dickinson and Company	$4.20	2.38%	+5.65%	126.51%	53 Years
BSX Boston Scientific	N/A	N/A	N/A	N/A	N/A
EW Edwards Lifesciences	N/A	N/A	N/A	N/A	N/A
STE STERIS	$2.52	1.06%	+9.40%	30.81%	20 Years

Latest STE, BSX, EW, and BDX Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/28/2026	BDX Becton, Dickinson and Company	quarterly	$1.05	2.53%	9/9/2026	9/9/2026	9/30/2026
7/30/2026	STE STERIS	quarterly	$0.69	1.19%	9/4/2026	9/4/2026	9/25/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BDX Becton, Dickinson and Company	0.55	0.87	0.51
BSX Boston Scientific	0.43	1.24	0.74
EW Edwards Lifesciences	0.06	4.52	3.77
STE STERIS	0.23	1.91	1.35

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BDX Becton, Dickinson and Company	86.97%
BSX Boston Scientific	89.07%
EW Edwards Lifesciences	79.46%
STE STERIS	94.69%

Insider Ownership

Company	Insider Ownership
BDX Becton, Dickinson and Company	0.40%
BSX Boston Scientific	0.34%
EW Edwards Lifesciences	0.31%
STE STERIS	1.12%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BDX Becton, Dickinson and Company	72,000	275.54 million	274.44 million	Optionable
BSX Boston Scientific	59,000	1.45 billion	1.44 billion	Optionable
EW Edwards Lifesciences	16,000	575.80 million	574.02 million	Optionable
STE STERIS	17,937	97.46 million	96.37 million	Optionable

STE, BSX, EW, and BDX Headlines

Recent News About These Companies

UBS Group Cuts STERIS (NYSE:STE) Price Target to $270.00

August 10 at 2:50 AM | americanbankingnews.com

STERIS's (STE) "Overweight" Rating Reiterated at Piper Sandler

August 10 at 1:48 AM | americanbankingnews.com

STERIS Q1 Earnings Call Highlights

August 9 at 4:02 AM | marketbeat.com

STERIS (NYSE:STE) Stock Rating Upgraded by Wall Street Zen

August 9 at 1:06 AM | americanbankingnews.com

STERIS (NYSE:STE) Raised to Buy at Wall Street Zen

August 9 at 1:05 AM | marketbeat.com

UBS Group Issues Pessimistic Forecast for STERIS (NYSE:STE) Stock Price

August 7 at 7:41 PM | marketbeat.com

STERIS (NYSE:STE) Given Overweight Rating at Piper Sandler

August 7 at 1:23 PM | marketbeat.com

STERIS plc (STE) Q1 2027 Earnings Call Transcript

August 6, 2026 | seekingalpha.com

Steris to invest $600M in North Carolina manufacturing hub

August 6, 2026 | finance.yahoo.com

NCRR Injecting $600K into Rail-Served STERIS Facility

August 6, 2026 | railwayage.comR

Public company behind $600M, 335-job North Carolina factory revealed

August 6, 2026 | bizjournals.com

Steris (NYSE:STE) posts Q2 CY2026 sales in line with estimates

August 6, 2026 | msn.com

STE Q1 Earnings Beat, Revenues Miss, Stock Dips in Aftermarket Trading

August 6, 2026 | zacks.com

5 Quality Stocks Set to Reward Investors With Dividend Hikes

August 6, 2026 | zacks.com

Steris: Fiscal Q1 Earnings Snapshot

August 6, 2026 | chron.com

Cetera Investment Advisers Sells 17,585 Shares of STERIS plc $STE

August 6, 2026 | marketbeat.com

STERIS (NYSE:STE) Announces Earnings Results

August 5, 2026 | marketbeat.com

Here's What Key Metrics Tell Us About Steris (STE) Q1 Earnings

August 5, 2026 | zacks.com

Steris (STE) Q1 Earnings Surpass Estimates

August 5, 2026 | zacks.com

STERIS (NYSE:STE) Issues FY 2027 Earnings Guidance

August 5, 2026 | marketbeat.com

STERIS Q1 Revenue Rises 7 Percent to $1.5 Billion

August 5, 2026 | quiverquant.comQ

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

STE, BSX, EW, and BDX Company Descriptions

Becton, Dickinson and Company NYSE:BDX

$176.53 -0.33 (-0.19%)

Closing price 08/7/2026 03:59 PM Eastern

Extended Trading

$176.13 -0.40 (-0.23%)

As of 07:53 AM Eastern

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.

Boston Scientific NYSE:BSX

$49.35 +0.04 (+0.09%)

Closing price 08/7/2026 03:59 PM Eastern

Extended Trading

$49.60 +0.25 (+0.50%)

As of 07:58 AM Eastern

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

Edwards Lifesciences NYSE:EW

$89.65 -0.07 (-0.08%)

Closing price 08/7/2026 03:59 PM Eastern

Extended Trading

$89.56 -0.09 (-0.09%)

As of 07:35 AM Eastern

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; INSPIRIS RESILLA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valves conduit for complex combined procedures; and MITRIS RESILIA valve. In addition, it offers critical care solutions, including hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings under the FloTrac, Acumen IQ sensors, ClearSight, Acumen IQ cuffs, and ForeSight names; HemoSphere, a monitoring platform that displays physiological information; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.

STERIS NYSE:STE

$237.70 +0.23 (+0.10%)

Closing price 08/7/2026 03:59 PM Eastern

Extended Trading

$237.48 -0.22 (-0.09%)

As of 07:37 AM Eastern

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services. It also provides capital equipment installation, maintenance, upgradation, repair, and troubleshooting services; preventive maintenance programs and repair services; instrument and endoscope repair and maintenance services; and custom process improvement consulting and outsourced instrument sterile processing services. The Applied Sterilization Technologies segment provides contract sterilization and testing services for medical device and pharmaceutical manufacturers through a network of approximately 50 contract sterilization and laboratory facilities. The Life Sciences segment designs, manufactures and sells consumable products, such as formulated cleaning chemistries, barrier, sterility assurance products, steam and vaporized hydrogen peroxide sterilizers, and washer disinfectors. This segment also offers equipment installation, maintenance, upgradation, repair, and troubleshooting services; and preventive maintenance programs and repair services. The Dental segment provides hand and electric-powered dental instruments, infection control products, conscious sedation, personal protective equipment, and water quality products for dental suite. The company serves its products and services to hospitals, other healthcare providers, and pharmaceutical manufacturers. The company was founded in 1985 and is based in Dublin, Ireland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest STE, BSX, EW, and BDX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest STE, BSX, EW, and BDX Earnings

Compare Dividends

Latest STE, BSX, EW, and BDX Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

STE, BSX, EW, and BDX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

STE, BSX, EW, and BDX Company Descriptions

Becton, Dickinson and Company NYSE:BDX

Boston Scientific NYSE:BSX

Edwards Lifesciences NYSE:EW

STERIS NYSE:STE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools